> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rezera, Formerly NodThera, Files For Nasdaq IPO With $3.9 Million In Cash And A Going-Concern Warning
- URL: https://www.bullished.co/rezera-formerly-nodthera-files-for-nasdaq-ipo-with-3-9-million-in-cash-and-a-going-concern-ebb9b8f0/
- Published: 2026-10-21T20:41:33.000Z
- Updated: 2026-11-05T20:30:39.000Z
- Description: The drug developer's S-1 shows no drug revenue, a $42.2 million 2025 net loss and blank offering terms.
- Author: Matteo Parrino
- Tags: Deals, Industry: Not classified

Rezera, the Boston drug developer formerly called NodThera, filed an [S-1 registration statement](https://www.sec.gov/Archives/edgar/data/0002141583/000110465926117853/tmq-20261021xdrsa.htm?ref=bullished.co) on Wednesday to list on Nasdaq, reporting [cash of $3.9 million](https://www.sec.gov/Archives/edgar/data/0002141583/000110465926117853/tmq-20261021xdrsa.htm?ref=bullished.co) as of June 30, 2026\. The filing also carries a going-concern warning, meaning management has concluded there is substantial doubt the company can keep operating for a year.

## The finding: a thin cash balance against rising losses

Rezera reported a net loss of $42.2 million for 2025, up from $25.2 million in 2024, and says it has never generated revenue from drug sales. Cash and cash equivalents were $3.9 million on June 30, 2026, and its accumulated deficit was $210.7 million.

The filing says recurring losses and negative operating cash flow led management to conclude there is substantial doubt about its ability to continue as a going concern. It adds that its current plans do not alleviate that doubt.

The company says it has raised $201.1 million in gross proceeds from convertible notes and preferred stock since it began. In July 2026 it sold Series D4 preferred stock for net proceeds of about $15.0 million and drew a $15.0 million term loan from Silicon Valley Bank. Pro forma for those steps, cash would have been $33.975 million.

The S-1 also discloses material weaknesses in internal financial controls. Rezera had 21 full-time employees as of June 30, 2026, according to the filing's risk factors.

## The catch: the lead drug has not been tested in the target disease

Rezera plans a single late-stage trial of its lead oral drug candidate, ruvonoflast, in peripheral artery disease, a condition that narrows leg arteries. The trial is planned to start in the first half of 2027, with a readout in 2028 and a new drug application targeted for early 2029.

The filing states that the company has not run clinical trials of ruvonoflast in patients with that disease. Its human data come from trials in other conditions, including a mid-stage cardiometabolic trial called RESOLVE-1\. The company reports inflammation-marker reductions there, such as a 56.4% cut in hsCRP, a blood marker of inflammation, at the 150 mg once-daily dose at week 4.

The company also says its business depends substantially on ruvonoflast, and that it will need substantial additional funding beyond current capital.

## What the offering looks like

The cover leaves the share count and the price range blank, so terms have not been set. Rezera intends to apply to list under the symbol "RZRA," and says completion of the offering is contingent on that listing. Jefferies, TD Cowen and Cantor are joint bookrunners.

The company says it will use proceeds, together with existing cash, to advance ruvonoflast through the planned trial, prepare for a commercial launch if approved, and fund its earlier pipeline. The name changed from NodThera Inc. to Rezera Inc. effective September 9, 2026.

A later amendment would need to fill in the share count and price range before any pricing.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [S-1 — Rezera Inc.](https://www.sec.gov/Archives/edgar/data/0002141583/000110465926117853/tmq-20261021xdrsa.htm?ref=bullished.co) — SEC EDGAR